Safety, Tolerability, and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Women
Launched by HRA PHARMA · Apr 19, 2010
Trial Information
Current as of May 15, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Having received ellaOne® as emergency contraception at the clinical site
- • Postmenarcheal adolescents or adult women
- • Willing to provide information on bleeding, sexual intercourses, method of contraception, concomitant medications and adverse events for the next two menstrual periods and to complete the diary accordingly
- • Willing to provide information on pregnancy outcome / delivery and newborn's health at delivery
- • Able to provide written informed consent
- • Willing to not participate in a clinical trial before the end of study participation
- Exclusion Criteria:
- • Currently participating in any interventional clinical trial (testing an Investigational Medicinal Product)
About Hra Pharma
HRA Pharma is a leading global pharmaceutical company focused on developing innovative healthcare solutions that address unmet medical needs. With a commitment to advancing patient care, HRA Pharma specializes in the research and development of products in areas such as women's health, endocrinology, and rare diseases. The company leverages a strong pipeline of clinical trials to deliver safe and effective therapies, while prioritizing ethical standards and regulatory compliance in all its operations. HRA Pharma's dedication to scientific excellence and patient-centric approaches positions it as a key player in the pharmaceutical industry, driving progress in healthcare for diverse populations worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Denver, Colorado, United States
Lakewood, Colorado, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Stockholm, , Sweden
Belfast, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials